BEATW

HeartBeam, Inc. Warrants provide holders with the right to purchase shares of HeartBeam common stock at a predetermined exercise price within a specified exercise period. These warrants were issued as part of previous financing transactions and trade separately from the common stock. Warrants offer investors leveraged exposure to HeartBeam's business prospects, with the potential for amplified returns if the company successfully commercializes its cardiac monitoring technology and the stock price appreciates significantly. The warrants gain intrinsic value when HeartBeam's stock price rises above the exercise price, at which point holders can exercise to purchase shares at the below-market strike price or sell the warrants in the secondary market. The warrant price also incorporates time value reflecting the remaining duration until expiration and the stock's expected volatility. This leverage characteristic means warrants can deliver outsized percentage gains during periods of stock appreciation but also carry higher risk, potentially declining more sharply during downturns and expiring worthless if the stock price remains below the exercise price at expiration. HeartBeam is commercializing its vectorelectrocardiography (VECG) technology platform, including the HeartBeam AIMIGo system—a credit card-sized, cable-free device that produces 12-lead ECG equivalent outputs for heart attack detection. The company has received FDA clearance and is focused on market development and adoption. Successful commercial launch, securing reimbursement, establishing clinical evidence, achieving revenue growth, or other positive business developments could drive stock price appreciation, creating value for warrant holders. These instruments suit investors with higher risk tolerance who believe in HeartBeam's technology and commercial potential in the cardiac monitoring market.